FDA Approves Second COVID-19 Booster for Americans 50+ – Consumer Health News
FDA Approves Second COVID-19 Booster for Americans 50+ – Consumer Health News

FDA Approves Second COVID-19 Booster for Americans 50+ – Consumer Health News

TUESDAY, March 29, 2022 (HealthDay News) – The U.S. Food and Drug Administration announced Tuesday that it has approved another booster shot of Pfizer and Moderna COVID-19 vaccines for people 50 years and older.

The agency also approved another booster for Americans 12 years and older who are immunocompromised, such as those who have undergone solid organ transplants. The extra shot can be given at least four months after an initial booster for both groups.

“Current evidence suggests some diminishing protection over time against severe COVID-19 outcomes in elderly and immunocompromised individuals,” said Peter Marks, MD, director of the FDA Center for Biological Evaluation and Research, in an agency. news release notice of approval. “Based on an analysis of new data, a different booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine may help increase the level of protection for those at higher risk.”

When the U.S. Centers for Disease Control and Prevention decides exactly who should get the extra shot, it will be immediately available to these Americans. The CDC is expected to say that people in the age group can get a fourth shot, instead of recommending it, and to highlight vulnerable populations within the age group that should get the shot, Washington Post reported.

Public health experts said they are getting harder and harder by advising their patients on whether or not to get another shot. “I’ve been getting several inquiries from lay friends over the last few days: ‘What does it mean and what should I do?'” John Moore, Ph.D., professor of microbiology and immunology at Weill Cornell Medicine in New York City , told mail. “I find it increasingly difficult to tell friends what to do. It’s getting really problematic.”

The primary benefit of a fourth shot is thought to be protection against serious illness, and this risk can vary dramatically among people 50 years and older. A host of factors – underlying health conditions, age and time since last booster dose or infection – all play a role in what a person should consider when weighing another booster.

Although no advisory panel meetings on other boosters are scheduled, the FDA has scheduled a meeting of its advisory committee on April 6 to discuss the administration’s overall future vaccine strategy.

Washington Post Article

Leave a Reply

Your email address will not be published.